<DOC>
	<DOCNO>NCT00466245</DOCNO>
	<brief_summary>A phase 2 study ass MVA smallpox vaccine previously vaccinate vaccine- naive subject three dose level .</brief_summary>
	<brief_title>Phase 2 Study Safety , Tolerability , Immunogenicity Three Dose Levels ACAM3000 Smallpox Vaccine</brief_title>
	<detailed_description>This study randomize , double-blind , placebo-controlled out-patient study conduct multiple center United States ( US ) . Up 700 healthy male female adult subject 18 55 year age ( inclusive ) , previously vaccinate subject naïve smallpox vaccine enrol . Subjects randomize 1 8 treatment group 100 ( 50 placebo ) subject per group receive either ACAM3000 MVA Smallpox Vaccine ( 1 3 dose level ) placebo Study Days 0 28 . All personnel associate trial blind treatment , exception study pharmacist prepares treatment administration subject . There 2 control group study . A comparison adverse event safety assessment placebo ACAM3000 MVA Smallpox Vaccine perform . In addition serve control safety , previously vaccinate subject receive placebo serve control antibody T-cell response person preexist immunity receive ACAM3000 MVA Smallpox Vaccine . Safety , tolerability , immunogenicity data 110 subject undergoing primary immunization grade dos ACAM3000 MVA Smallpox Vaccine available follow completion Acambis protocol H-249-001 , ongoing phase I clinical trial . The dos level study may change follow availability result protocol H-249-001 . Statistical analysis focus comparison among dose level ACAM3000 MVA Smallpox Vaccine comparison ACAM3000 MVA Smallpox Vaccine placebo , appropriate . A separate analysis perform previously vaccinate naïve subject . Descriptive statistic use compare demographic baseline clinical data stratum .</detailed_description>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>subject must good general health , check toxicity grade table . previously vaccinated subject must age 33 55 previous vaccine 10 year ago . vaccine naive subject must age 18 32 , never vaccinate smallpox . Female subject must pregnant lactating . Subjects participate `` first responder '' program . history immunodeficiency . autoimmune disease history cardiac disease diagnose risk factor ischemic coronary disease history heart palpitation abnormality cardiac rhythm . current history eczema description . Known allergy MVA component , include egg egg product . morbid obesity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>MVA Vaccine</keyword>
</DOC>